Stanley Druckenmiller’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stanley Druckenmiller’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-88,910	Closed	-$21.1M	–	49
2022 Q4	$21.1M	Hold	88,910	–	–	1.05%	20
2022 Q3	$17.8M	Buy	+88,910	New	+$17M	1.01%	25
2022 Q2	–	Sell	-63,945	Closed	-$10.4M	–	44
2022 Q1	$10.4M	Buy	+63,945	New	+$9.74M	0.45%	27
2020 Q4	–	Sell	-368,419	Closed	-$53.6M	–	57
2020 Q3	$53.6M	Hold	368,419	–	–	1.56%	18
2020 Q2	$54.6M	Hold	368,419	–	–	1.67%	19
2020 Q1	$40.1M	Buy	368,419 +252,250	+217%	+$29.1M	1.63%	17
2019 Q4	$13.4M	Buy	+116,169	New	+$11.6M	0.39%	40

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Stanley Druckenmiller's ALNY Position: Q1 2023 in Review

Stanley Druckenmiller sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 88,910 shares — an estimated $21.1M sold.

Stanley Druckenmiller first reported a position in ALNY in Q4 2019 and held it in 7 quarters. The position peaked at $54.6M in Q2 2020. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

Stanley Druckenmiller reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Stanley Druckenmiller sold 88,910 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $21.1M.
Stanley Druckenmiller first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Stanley Druckenmiller's Alnylam Pharmaceuticals position peaked at $54.6M in Q2 2020.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on Duquesne Family Office's 13F filing for Q1 2023, filed 15 May 2023.